Nubilaria provides free EDC for pro bono COVID-19 related ARDS study
Nubilaria is providing it’s innovative ACTide EDC system free in support of a clinical study for COVID-19 related ARDS intensive
Read more
Latest
Sanofi’s MenQuadfi meningococcal (MenACWY) vaccine gets FDA nod
The FDA has shown green light for MenQuadfi, Sanofi’s innovative meningococcal (MenACWY) vaccine. The U.S. Food and Drug Administration (FDA)
Read more
FUJIFILM’s Avigan Tablet for COVID-19 to be Free for 20 Countries
While COVID-19 transmission is expanding, the Japanese government has agreed to raise its Avigan® Tablet (favipiravir) stockpile, which is estimated
Read more
Nubilaria offers ACTide EDC platform free to help battle COVID-19
Italian IT and complex database consultancy Nubilaria is offering it’s cutting edge ACTide EDC web platform free of charge to
Read more
The top 10 Pharmaceutical Innovation Index companies 2020
Success on the Innovation Index is important, especially now, at a time when innovation is needed more than ever. Many,
Read more
Abbott’s molecular point-of-care COVID-19 test could be a gamechanger
At the end of March, the American medical devices and healthcare company Abbott Laboratories announced that the U.S. Food and
Read more
FDA grants Emergency Use Authorisation for Roche’s Coronavirus Test
Roche’s coronavirus test has been granted Emergency Use Authorization by the U.S. Food and Drug Administration, the Swiss pharma giant
Read more
Who is developing the Novel Coronavirus Vaccine?
With more than 100,000 confirmed novel coronavirus cases reported across 93 countries and 3400+ deaths, a coronavirus vaccine is needed
Read more
Coronavirus (COVID-19) Exposing Global Drug Supply Chain Worries
China, which is at the epicenter of the coronavirus (COVID-19) outbreak, is the world’s key supplier of chemical and pharmaceutical
Read more
Coronavirus biotechnology stocks defying gravity
This week, biotechnology stocks on the verge of developing a coronavirus vaccine skyrocketed as the deadly virus sent the US
Read more